Researchers have newly identified a universal, essential biomarker for the childhood cancer neuroblastoma – and a potential new target for treatment.
Beam takes its time to the clinic; Aspen gets clearance to test Parkinson’s cell therapy in humans
Over a year and a half since Beam Therapeutics received clearance from the FDA to test its base-edited sickle cell therapy in humans, it has